Pitfalls in accurate estimation of overdiagnosis: implications for screening policy and compliance
- PMID: 23927453
- PMCID: PMC3978609
- DOI: 10.1186/bcr3448
Pitfalls in accurate estimation of overdiagnosis: implications for screening policy and compliance
Abstract
Stories in the public media that 30 to 50% of screen-detected breast cancers are overdiagnosed dissuade women from being screened because overdiagnosed cancers would never result in death if undetected yet do result in unnecessary treatment. However, such concerns are unwarranted because the frequency of overdiagnosis, when properly calculated, is only 0 to 5%. In the previous issue of Breast Cancer Research, Duffy and Parmar report that accurate estimation of the rate of overdiagnosis recognizes the effect of lead time on detection rates and the consequent requirement for an adequate number of years of follow-up. These indispensable elements were absent from highly publicized studies that overestimated the frequency of overdiagnosis.
Comment on
-
Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time.Breast Cancer Res. 2013 May 16;15(3):R41. doi: 10.1186/bcr3427. Breast Cancer Res. 2013. PMID: 23680223 Free PMC article.
References
-
- Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;15:1778–1786. - PubMed
-
- Puliti D, Duffy SW, de Koning H, Lynge E, Zappa M, Paci E. EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;15(Suppl 1):42–56. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources